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Elucidation of tumour suppression mechanisms is a major
challenge in cancer biology. Therefore, Peto’s paradox, or
low cancer incidence in large animals, has attracted focus.
According to the gene-abundance hypothesis, which considers
the increase/decrease in cancer-related genes with body
size, researchers evaluated the associations between gene
abundance and body size. However, previous studies only
focused on a few specific gene functions and have ignored
the alternative hypothesis (metabolic rate hypothesis): in
this hypothesis, the cellular metabolic rate and subsequent
oxidative stress decreases with increasing body size. In
this study, we have elected to explore the gene-abundance
hypothesis taking into account the metabolic rate hypothesis.
Thus, we comprehensively investigated the correlation
between the number of genes in various functional categories
and body size while at the same time correcting for the mass-
specific metabolic rate (Bc). A number of gene functions that
correlated with body size were initially identified, but they
were found to be artefactual due to the decrease in Bc with
increasing body size. By contrast, immune system-related
genes were found to increase with increasing body size when
the correlation included this correction for Bc. These findings
support the gene-abundance hypothesis and emphasize the
importance of also taking into account the metabolic rate
2016 The Authors. Published by the Royal Society under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted
use, provided the original author and source are credited.
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when evaluating gene abundance–body size relationships. This finding may be useful for
understanding cancer evolution and tumour suppression mechanisms as well as for determining
cancer-related genes and functions.
1. Introduction
Cancer is a complex and robust disease that remains difficult-to-treat despite the development of
numerous anti-cancer therapies [1,2]. Elucidation of cellular tumour suppression mechanisms is a long-
standing goal for cancer researchers. In recent years, Peto’s paradox, first reported in 1975 [3], has
attracted renewed attention to this topic [4]. This paradox is often explained as follows: assuming
that the probability of normal cells transitioning to cancer cells is equivalent among all cells, larger
animals (i.e. organisms with more cells) are expected to show a higher incidence of cancer. However,
a positive correlation between body size (or mass) and cancer incidence has not been observed [4–6].
In fact, previous studies have reported no association between body size and cancer incidence (and
also the lifespan-adjusted equivalent) [7,8]. These results indicate the existence of body-size-dependent
mechanisms of tumour suppression.
Several hypotheses have been proposed to resolve Peto’s paradox (or to explain body-size-dependent
suppression mechanisms). The metabolic rate hypothesis [9,10] is particularly interesting because cancer
cells have altered glucose metabolism in that they typically possess enhanced aerobic glycolysis (the so-
called Warburg effect). This hypothesis states that larger animals have relatively lower cancer incidence
because the metabolic (oxygen consumption) rate per unit body mass, which is roughly equal to the
rate at the cellular level, decreases with body size. Oxygen radicals often enhance ontogenetic mutations
and induce the transition from normal cells to tumour cells. In short, large animals have lower cancer
rates, because they can avoid oxidative stress and subsequent genetic mutations. In fact, oxidative DNA
damage is associated with metabolic rate [11], and the mutation rate decreases with body size because
of the decrease in the mass-specific metabolic rate [12,13]. The negative correlation between mass-
specific metabolic rate (Bc) and body mass (M) is well known in the context of Kleiber’s Law (or the
allometric scaling of metabolic rate) [14–16]; in particular, the relationship between metabolic rate (B) and
body mass is generally described as a power-law function: B∝M3/4. Thus, mass-specific metabolic rate
shows a power-law decay with body mass: Bc =B/M∝M−1/4. The metabolic rate hypothesis may show
promise for resolving Peto’s paradox; however, it is unsuitable for investigating the cellular (microscopic)
mechanisms of tumour suppression, because it is based on physiology (macroscopic behaviour). In
addition to this, the basis for allometric scaling of metabolic rate is still unclear even though several
hypotheses, or models, have been proposed [17–21].
Genetic studies are useful in this context. In particular, a number of cancer-related genes (e.g.
tumour suppressor genes (TSGs) and oncogenes) and pathways [22,23] have been identified by several
new technologies including the use of high-throughput methods. Previous studies have proposed an
alternative hypothesis: the gene-abundance hypothesis [5,24,25], which states that larger animals have more
(and/or more highly expressed) genes that suppress cancer progression (e.g. TSGs) and fewer (and/or
more lowly expressed) genes that induce cancer growth. Further theoretical and experimental studies
have provided deeper insights into this hypothesis. For example, a theoretical study [24] showed that
the number and/or expression levels of (proto-)oncogenes decreases with increasing body size, whereas
the number and/or expression levels of TSGs are hardly correlated with body size because of energetic
limitations. In particular, the increase of TSGs requires energetic costs resulting from repairing mutations
and reproduction; thus, such an evolutionary strategy (i.e. the increase of TSGs) for cancer suppression
is hardly adopted (see [24] for details). A comparative genomic study [26] demonstrated that bowhead
whale-specific gene mutations were linked to cancer and ageing; moreover, it reported that duplications
frequently occurred in genes related to DNA-repair, cell cycle and ageing. Another study [8] showed that
elephants have a larger TP53 copy number, which is a well-known TSG, compared with other mammals,
and also reported that elephant cells are more resistant to DNA damage, than human cells. Retroviral
integration can also induce cancer. A previous study [27], based on bioinformatics and mathematical
biology, has shown that the levels and activity of endogenous retroviruses (ERVs) acquired in the last
10 Myr decrease with body size; it was also reported that the mean age of ERVs increases with body size.
Inspired by the fact that cancer cell mutations directly increase the number of microsatellites in tumour
DNA [28], researchers have revealed that the number of microsatellites decreases with body size [29].
Taken together, these results support the gene-abundance hypothesis.
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However, a more careful examination may be required to prove the validity of the gene-abundance
hypothesis. Previous studies have only focused on the relationship between specific biological functions
and body size, and they generally compared functions among a few mammals. The effect of metabolic
rate (i.e. the metabolic rate hypothesis) also needs to be considered when investigating the gene
abundance–body size relationships. The gene-abundance hypothesis may therefore be overlapping with
the metabolic rate hypothesis. In particular, it remains possible that the gene abundance–body size
relationships are spurious correlations that result from the body-size-dependent metabolic rate. For
example, the number of genes in a functional category (NOGF) generally shows a positive correlation
with the mass-specific metabolic rate [30] (i.e. a number of functional categories are associated with
mass-specific metabolic rate). This fact predicts that NOGF will generally show a negative correlation
with body size because of the negative association between mass-specific metabolic rate and body
size. Moreover, oncogenes and tumour suppressors are known to regulate metabolism (reviewed
in [9,10]). For example, Myc is an oncogene that is known to regulate glycolysis and to activate
mitochondrial biogenesis, whereas the p53 protein, which is a tumour suppressor, is known to inhibit
glycolysis. Glycolysis and biogenesis are strongly related to respiration (i.e. metabolic rate). Assuming
that oncogenes generally increase the metabolic rate at the cellular level and that TSGs decrease it, the
number of oncogenes and TSGs are expected to show negative and positive associations with body size,
respectively. This expectation is consistent with the prediction from the gene-abundance hypothesis.
Therefore, we performed an integrated evaluation of the metabolic rate hypothesis and the gene-
abundance hypothesis. In particular, genomic data, metabolic rate and body size for mammals were
collected from public databases and the literature, and using statistical methods, the relationships
between NOGF and body size were investigated by removing the effect of mass-specific metabolic rate.
2. Material and methods
2.1. Data on metabolic rate, body mass and genome
We used data on mammalian metabolic rates and body masses obtained in our previous study [30].
Additionally, we also collected data for those mammals whose genomes were available in a species-
level database within the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [31]. The units
of mass-specific metabolic rate and body mass were converted to watts per gram (W/g) and grams (g),
respectively. To reduce the phylogenetic signals, one representative species was selected from each genus,
according to the year in which the species genome sequence was first completed. Finally, we obtained
data for 33 mammals (electronic supplementary material, table S1).
2.2. Functional categories of genes
The method we used is almost similar to that reported in our previous study [30]. We used the third level
of KEGG BRITE Functional Hierarchy [32] in the KEGG metabolic map (www.genome.jp/kegg-bin/
get_htext?br08901.keg) for measuring the number of genes in functional categories. We downloaded
the data on functional category–gene identifier relationships of species S from the KEGG FTP site
(ftp.bioinformatics.jp/kegg/brite/organisms/S/S00001.keg) on 9 May 2015, where S corresponds to
the KEGG organism identifier (electronic supplementary material, table S1). In this study, we did not
consider Gene Ontology (GO) [33] as an alternative definition of functional categories because there
were fewer organisms whose annotations in the GO database were completed, compared to those in the
KEGG database. In addition, we selected TSGs and oncogenes identified in the literature [22,23]. In total,
we investigated 342 functional categories.
2.3. Statistical analysis
Statistical analysis was performed using R software (v. 3.2.4; www.r-project.org). The association
between NOGF and body size/mass-specific rate was evaluated based on the Pearson’s product-moment
correlation coefficient r and its associated p-value. Mass-specific metabolic rate and body mass were
log-transformed for all analyses. To evaluate NOGF–body size correlations when the mass-specific
metabolic rate was kept constant, the partial correlation analysis was considered; in particular, we used
the pcor function that is available in the R package ppcor (v. 1.1). Additionally, we also considered a
multivariate analysis; in particular, the standardized partial regression coefficient for M in the formula
NOGF ∼M+Bc (i.e. the Bc-corrected estimate) was calculated for each functional category using the lm
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function (electronic supplementary material, tables S2 and S3). We used the lm function to calculate the
residuals for variables.
To find the functional categories that are specifically associated with body size, we used an enrichment
analysis based on Fisher’s exact test, inspired by gene set enrichment analysis [34]. In particular, for the
KEGG BRITE Functional Hierarchy we focused on the second and third functional hierarchical levels
and calculated the statistical significance, defined as −log10(p-value using Fisher’s exact test), for the
ratio of functional categories (i.e. the categories at the third level) correlated with body size (p< 0.05) to
all the functional categories in the upper (i.e. second-level) category. The fisher.test function was used to
perform Fisher’s exact test. The changes in the p-value threshold for the NOGF–body size correlations
did not significantly affect the conclusion.
2.4. Phylogenetically independent contrasts
Phylogenetically independent contrasts (PICs) [35] of the variables were evaluated in order to
remove any possible phylogenetic effect on the association between biological variables in the
context of the phylogenetic comparative analysis [36,37]. This method is similar to that used in
our previous study [38]. In particular, the mammalian phylogenetic tree was constructed using the
matrix extracellular phosphoglycoprotein precursor (MEPE) gene (electronic supplementary material,
figure S1), downloaded from the KEGG database on 20 August 2015. Note that the platypus,
Ornithorhynchus anatinus, was omitted from the tree because the MEPE gene for this species was not
found. Based on the phylogenetic tree, the PICs were calculated using the function pic in the R package
ape (v. 3.4).
3. Results
3.1. The number of genes in functional categories generally show a negative correlation
with body size
We found that NOGF was generally associated with body size. Genome size and the total number of
genes (proteins) did not affect the observed NOGF–body size correlations because body size did not
correlate with either genome size (r=−0.054, p= 0.77) or number of proteins (r=−0.17, p= 0.35).
In general, the associations observed were negative (figure 1a). In particular, the mean of r was −0.14
(95% CI, from −0.16 to −0.12). About 13% (43/342) of the functional categories showed a statistically
significant correlation with body size (p< 0.05; also the electronic supplementary material, table S2).
For example, the number of oncogenes decreases with body size (r=−0.38, p= 0.031); by contrast,
the number of TSGs shows no correlation with body size (r=−0.28, p= 0.11). This result supports
the gene-abundance hypothesis and is consistent with the theoretical prediction [24] that the number
of oncogenes decreases with body size, whereas the number of TSGs is almost independent of body
size due to reproduction. In addition, disease incidence (and by inference disease-related genes) also
decreases with increasing body size. For instance, body size was negatively associated with viral
myocarditis (r=−0.63, p= 8.0 × 10−5), type I diabetes mellitus (r=−0.57, p= 6.1 × 10−4), and graft-
versus-host disease (r=−0.55, p= 3.7 × 10−3). These observed negative associations could be considered
reasonable because these diseases possibly arise due to cancer treatment and/or because they increase
the incidence of cancer [39–41]. Therefore, this result also supports the gene-abundance hypothesis.
3.2. Body-size-dependent metabolic rate strongly influences correlations between the number
of genes in functional categories and body size
A conclusion that the gene-abundance hypothesis is correct needs to be made with caution, because it
remains possible that the observed associations are spurious. For some of the functional categories, the
NOGF–body size relationships were found to be questionable. For example, the relationship between
cancer and transduction of taste signals could not be explained biologically although a negative
correlation between NOGF and body size was clearly observed (r=−0.57, p= 6.9 × 10−4; see also §3.3).
Similarly, the association between serotonergic synapses and body size (r=−0.48, p= 5.2 × 10−3) could
also not be readily explained in the context of tumour biology. We can, however, speculate that the
observed association may suggest a role for serotonin in cancer, because low doses of serotonin are
known to inhibit cancer growth by decreasing tumour blood supply [42]. It should be noted that blood
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Figure 1. Distribution of the correlation coefficient between the NOGF and body mass (M). Mass-specific metabolic rate (Bc) correction
was (a) not considered (b) considered. The filled area indicates the p-value of less than 0.05.
supply is positively correlated with metabolic rate [15,17]. In summary, these observations suggest
the possibility that genetic changes may have an indirect effect on cancer. In particular, the genetic
change does not contribute directly to the inhibition or enhancement of cancer growth; rather it implies
that genetic changes (e.g. increase/decrease in NOGFs) lead to a change in metabolic rate, which
then influences cancer growth. Therefore, the noted differences in metabolic rate according to body
size should be taken into consideration when evaluating NOGF–body size associations. In particular,
NOGFs are expected to show negative correlations with body size, because they are positively correlated
with mass-specific metabolic rate which itself is negatively correlated with body size. In fact, all the
statistically significant correlations that were observed, were negative (figure 1a); moreover, the observed
NOGF–body mass negative correlation was not concluded when corrected with the mass-specific
metabolic rate using the partial correlation analysis (figure 1b).
Additional results suggest the influence of metabolism on the NOGF–body size relationship. In
particular, functional categories related to metabolism were frequently observed (see the following
section for details). For example, body size was linked to lipid metabolism (e.g. fatty acid degradation
(figure 2a; r=−0.46, p= 6.7 × 10−3) and fatty acid biosynthesis (r=−0.50, p= 3.3 × 10−3)) as well as
nucleotide (pyrimidine) metabolism (r=−0.52, p= 1.7 × 10−3). Lipid metabolism [10,43] and nucleotide
metabolism [10,44] are known to play important roles in cancer. However, their role in cancer is often
considered in the context of energy regulation, which of course is related to metabolic rate [16]. In
addition, fatty acids are believed to determine metabolic rate (the so-called membrane-pacemaker hypothesis
[45–47]). In fact, the number of genes involved in lipid metabolism is known to be correlated with the
mass-specific metabolic rate [30]. In our dataset, the number of genes involved in fatty acid degradation
was also positively correlated with mass-specific metabolic rate (figure 2b; r= 0.49, p= 3.4 × 10−3).
For all functional categories, we calculated the correlation coefficient between the NOGF–body mass
(M) correlation and the NOGF–mass-specific metabolic rate (Bc) correlation (figure 2c). Assuming that
the mass-specific metabolic rate influences the NOGF–M correlation, a negative association between
the NOGF–M correlation and the NOGF–Bc correlation was observed due to the observed negative
correlation between mass-specific rate and body mass (r=−0.95, p< 2.2 × 10−16): Bc ∝M−0.24 ± 0.01.
As expected, this negative association was confirmed (figure 2c; r=−0.96, p< 2.2 × 10−16). This result
indicates that the observed NOGF–M correlations result from the Bc–M correlation.
3.3. Immune system-related genes increase with body size when the mass-specific metabolic
rate is kept constant
We used a partial correlation analysis to eliminate the effect of the mass-specific metabolic rate on the
NOGF–M correlations, and found that the NOGF–M associations for functional categories changed
significantly (figure 3). In particular, the NOGF–M associations, identified by a simple correlation
analysis, were not observed when the effect of metabolic rate was considered. For example, the observed
NOGF–M correlation for taste transduction (figure 3a; r=−0.57, p= 6.9 × 10−4) was not observed when
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and Bc.
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Figure 3. Change in the relationship between the NOGF and bodymass (M). (a) NOGF–M correlation for taste transduction. (b) NOGF–M
correlation for taste transduction correctedwith themass-specificmetabolic rate (Bc). (c) Scatter plot for the determination of coefficient
(R2) of NOGF–M correlation versus R2 of NOGF–M correlation corrected with Bc. The solid line indicates the diagonal line.
corrected for the mass-specific metabolic rate (figure 3b; rp = 0.013, p= 0.94). This indicates that most
of the observed correlations were artefacts likely occurring due to the body-size-dependent mass-
specific metabolic rate. Moreover, the mean of rp was positive (0.054 (95% CI, from 0.036 to 0.072);
see also figure 1b), unlike in the case of simple correlation analysis where the metabolic rate effect
was not considered (figure 1a). Around 6% (20/342) of the functional categories showed a statistically
significant correlation with body size (p< 0.05; see also the electronic supplementary material, table S2).
Representative examples of the functional categories that were correlated with body mass when the
mass-specific metabolic rate was kept constant are shown in table 1. For example, the increase in
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Table 1. Correlations between the NOGF and bodymass. The partial (mass-specificmetabolic rate-corrected) correlation coefficients (rp)
and correlation coefficients (r) are shown. The functional categories are only represented when the p-value is less than 0.01 using the
partial correlation analysis (see electronic supplementary material, table S2 for the full version), and they are displayed in descending
order of rp. Parenthetic values indicate the p-values.
Bc-corrected G–M correlation G–M correlation
upper category functional category rp (p-value) r (p-value)
immune system toll-like receptor signalling pathway 0.51 (3.2× 10−3) 0.18 (0.32)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
immune system FcεRI signalling pathway 0.50 (4.0× 10−3) 0.12 (0.49)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
transport and catabolism regulation of autophagy 0.49 (4.4× 10−3) 0.0029 (0.99)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
immune system RIG-I-like receptor signalling pathway 0.49 (4.9× 10−3) 0.15 (0.40)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
immune system natural killer cell-mediated cytotoxicity 0.46 (8.1× 10−3) −0.21 (0.24)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
signalling molecules and interaction cytokine–cytokine receptor interaction 0.45 (9.0× 10−3) 0.082 (0.65)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
the number of genes in the Toll-like receptor signalling pathway (figure 4a) may contribute to cancer
resistance, because this pathway plays an important role in host defence from infection [48]. The
other signalling pathways, identified based on NOGF–body size correlations, are also expected to
contribute to the resistance against cancer. In particular, the IgE-mediated allergic reaction mediated by
FcεRI signalling has been proposed as a target for cancer immunotherapy [49]. The RIG-I-like receptor
signalling pathway has been shown to be activated in cancer therapies through endogenous non-coding
RNAs [50]. The increase in the number of genes involved in the regulation of autophagy (figure 4b)
may be explained in the context of the protective function of autophagy to limit tumour necrosis and
inflammation [51]. Since natural killer cells contribute to the killing of tumour cells without a required
immunization or deliberate activation [52], the increase in the number of natural killer cell genes that
mediate cytotoxicity can be expected to enhance resistance against cancer. Cytokine interactions are
also known to be important in the context of cancer pathogenesis and cancer therapy [53]. It should be
noted that these functional categories were identified only when the correlation based on mass-specific
metabolic rate was considered.
The functional categories that were correlated with body mass were enriched in the immune system
(red bars in figure 5). This result indicates that the number of immune system-related genes generally
increases with body size. On the contrary, no clear pattern was found when the effect of metabolic rate
was ignored (blue bars in figure 5) even though such functional categories were enriched in lipid and
nucleotide metabolism.
We did not consider PICs in the above analyses because of the alternative methodology we used (see
§2.4 for details) and because there are limitations to phylogenetic comparative analysis. In particular,
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Figure 5. Enrichment of functional categories correlated with body size. The blue bars and red bars indicate the case that mass-specific
metabolic rate (Bc) correction was not considered for evaluating the relationships between the NOGF and body mass (M) and the case
that Bc correction was considered for evaluating NOGF–M correlations, respectively.
phylogenetic comparative analysis assumes a Brownian motion-like evolution of biological traits on
a phylogenetic tree with accurate branch lengths and may thus result in misleading conclusions.
In addition, statistical power decreases when a dataset is reduced in size following phylogenetic
corrections [54]. Despite these caveats, almost identical conclusions were obtained when PICs were
considered (electronic supplementary material, table S3). Therefore, phylogenetic effects did not
influence the outcome of this study.
4. Discussion
We comprehensively evaluated the gene-abundance hypothesis in the context of the metabolic rate
hypothesis, and found that NOGF generally showed a negative correlation with body size. However,
such associations were found to be artefactual due to the relationship between metabolic rate and body
mass. In particular, the result of the NOGF–body size correlations was significantly different when
the analysis was corrected for metabolic rate. Moreover, NOGF tended to be related to metabolic rate
rather than to cancer. When evaluating the NOGF–body size relationships corrected for metabolic rate,
we found that immune system-related genes increased with body size. A number of previous studies
support the notion that gene functions identified based on metabolic rate-corrected NOGF–body size
relationships are reasonable in the context of tumour suppression and cancer therapies. This result was
obtained only when the metabolic rate was kept constant, indicating that cancer-related genes/functions
could easily be overlooked when the difference in metabolic rate according to body size is not considered.
These results emphasize the importance of metabolic rate in evaluating gene abundance–body size
relationships.
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In recent years, researchers in this area have focused on the genomes of large animal (e.g. whales [26]
and elephants [8]) to test the gene-abundance hypothesis. However, such studies did not consider the
effect of metabolic rate and therefore may provide misleading conclusions. Our results do not contradict
those from previous studies because of the strong relationship between metabolism and cancer [10];
however, the NOGF–body size associations identified when the effect of metabolic rate was ignored
should be considered in the context of the metabolic rate hypothesis rather than the gene-abundance
hypothesis. Our results provide significant support for the gene-abundance hypothesis. In particular,
we have shown that the hypothesis is supported in a broad range of mammals, even though previous
studies have generally focused on large animal to small animal comparisons.
However, more careful analyses may be required in further studies. For example, our conclusion (the
importance of immune system, in particular) is still debatable because we only performed correlation
analyses. In this context, a multivariate analysis would be more appropriate. However, in this study we
could not perform such an analysis because of the multi-collinearity that arises from the fact that there
was gene overlap among functional categories. In fact, we were unable to calculate partial regression
coefficients and associated p-values because of singularities in the generalized linear model. As
mentioned in our previous study [30], this is a particular problem in GO analysis. To resolve this problem,
for example, we will need to define alternative (e.g. non-overlapping) functional categories (see below
for details). Despite these limitations, the bulk of the experimental evidence supports our conclusions.
It should also be noted that we evaluated NOGFs–body size associations by assuming that the Peto’s
paradox is correct. However, ideally, we need to consider the relationship with actual cancer incidence
rates in animals. In this study, we did not consider the actual cancer incidence rates because only
limited data are available. However, recent studies have begun to investigate cancer rates in wildlife
(e.g. reviewed in [55]). The data on cancer risks obtained in these studies will be very useful in further
studies. In addition to this, factors like lifespan, generation time and mutation rate are also different
across species; however, because it is believed that these biological parameters are related to metabolic
rate, a correction based on mass-specific metabolic rate may be the most useful one to remove most of
the effects of these biological parameters [11,13,16,56]. A critical review [57] claims that Peto’s paradox
relies on several questionable assumptions, and it emphasizes the importance of organ-level comparisons
rather than species-level comparisons in addressing the variation in cancer risk across tissues [58]. The
differences in risk may be explained in terms of differences in the number of tissue cell divisions [58] as
well as differences in the robustness of cancer signalling networks [59,60].
Another consideration is that the definition of gene abundance is controversial. For simplicity, we
have only considered the NOGF as an indicator of gene abundance. However, gene abundance could
also be measured in terms of expression level, copy number and activity of functional genes. Indeed,
a previous study reported that elephants show a higher expression level and copy number of TP53,
compared to humans. It is also possible that the body-size-dependent metabolic rate can give rise to
differences in gene expression and copy number, because the expression levels of (enzymatic) genes
are also known to determine metabolic rate [61,62]. Thus, the correction for metabolic rate may also
be required when considering the relationships between body size and expression level, copy number
and/or activity. We attempted to consider expression levels using gene expression data from various
mammalian organs [63]; however, a comprehensive analysis was not possible because of the limited
amount of data available. The measurement of gene abundance at the organ level using high-throughput
techniques (e.g. microarray and RNA-Seq [64]) should therefore be undertaken for a wide range of
organisms in the future.
As is the case for other genome analysis studies, our study has some general limitations. For example,
we only considered organisms for which genome sequences were completed and available; thus, our
species selection was unintentionally biased. In this context, metagenomic techniques may help to
complete the genomes of more organisms. Moreover, our findings depend significantly on the quality
of genome annotation. The functional categories, defined by the KEGG BRITE Functional Hierarchy in
this study, might be somewhat arbitrary (i.e. they depend on the opinions of database administrators).
Computational frameworks may increase the quality of genome annotation in terms of protein function
prediction (e.g. machine learning-based methods [65]); they may also provide alternative definitions of
functional categories. For example, computational methods based on the following frameworks may
be useful; graph clustering or community detection of networks [66], biosynthetic capability [67], gene
clusters and chemical transformation patterns [68,69].
Despite the limitations of our data analysis, these findings enhance our understanding of cancer
evolution and tumour suppression mechanisms with respect to body size. Furthermore, they may be
usefully applied in future research for estimating cancer-related genes and functions.
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